FDA Accepts Rezzayo Application For Preventing Fungal Disease, Grants Priority Review With Q1 2027 Target Date
CorMedix says the FDA accepted the filing and set a first-quarter 2027 target action date, with promotion aimed at the second half of 2027.
The FDA has accepted for filing a supplemental application to approve CorMedix's antifungal Rezzayo for preventing invasive fungal disease and granted it Priority Review, the company said in an 8-K filed Monday. The agency's target action date falls in the first quarter of 2027.
What the filing says
The application, a supplemental New Drug Application, was submitted by Mundipharma, CorMedix's global development partner, according to the press release attached to the filing. The FDA set its target date under the Prescription Drug User Fee Act.
The filing rests on ReSPECT, a late-stage pivotal study for which CorMedix announced positive topline results in April. It compared once-weekly rezafungin with a standard antimicrobial regimen for preventing invasive fungal disease in adults undergoing allogeneic stem cell transplants.
Rezzayo is approved by the FDA only for candidemia and invasive candidiasis in adults and pediatric patients 12 or older with limited or no alternative treatment options. The release says it is not approved for prevention, and its safety and efficacy for that use have not been established.
What it changes
CorMedix is targeting the second half of 2027 to begin promotional efforts if the FDA approves the new use. CEO Joseph Todisco said the company will "begin to prepare for a potential promotional launch in the second half of 2027."
The company also cautions that acceptance for filing and Priority Review "do not assure approval." Its risk language says the FDA could request more data or analyses, extend the review, or approve with narrower labeling than requested. It adds that ReSPECT topline data may change as more patient data become available.
The release says rezafungin has orphan drug exclusivity through 2035 and U.S. patent coverage through 2038. In market data, CorMedix shares were quoted at $7.26 in a Monday 8:01 a.m. ET snapshot, against a previous close of $7.46.
Next dated markers: the FDA's target action date in the first quarter of 2027, and a promotional launch aimed at the second half of 2027 if approval comes.
Sources
- 8-K Filing — CorMedix Inc. (CRMD) — SEC EDGAR
- Exhibit ea030895701ex99-1.htm — CorMedix Inc. 8-K exhibit — SEC EDGAR